Literature DB >> 26650691

Pseudotyping of lentiviral vector with novel vesiculovirus envelope glycoproteins derived from Chandipura and Piry viruses.

Shuang Hu1, Dipu Mohan Kumar1, Chelsea Sax1, Clayton Schuler1, Ramesh Akkina2.   

Abstract

While the envelope glycoprotein of vesicular stomatitis virus (VSV-G) is widely used for pseudotyping of lentiviral vectors, sub-optimal gene transfer into certain cell types and its sensitivity to inactivation by human complement hinders its broader applications. To find alternative candidates, here we evaluated two serologically distinct novel viral envelopes derived from Chandipura (CNV-G) and Piry (PRV-G) vesiculoviruses. Both permitted generation of high titer psuedotyped lentiviral vectors with a capacity for high efficiency gene transfer into various cell types from different species. In human lymphoid and hematopoietic stem cells, their transduction efficiency was significantly lower than that of VSV-G. However, both novel envelopes were found to be more resistant to inactivation by human serum complement compared to VSV-G. Thus CNV-G and PRV-G envelopes can be harnessed for multiple uses in the future based on the cell type that needs to be gene transduced and possibly for in vivo gene transfer.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chandipura and Piry viral glycoproteins; Gene transduction with pseudotyped lentiviral vectors; Human serum resistant lentiviral vectors; Lentiviral vector pseudotyping

Mesh:

Substances:

Year:  2015        PMID: 26650691      PMCID: PMC5898928          DOI: 10.1016/j.virol.2015.11.012

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  35 in total

1.  High-level transgene expression in human hematopoietic progenitors and differentiated blood lineages after transduction with improved lentiviral vectors.

Authors:  P Salmon; V Kindler; O Ducrey; B Chapuis; R H Zubler; D Trono
Journal:  Blood       Date:  2000-11-15       Impact factor: 22.113

2.  Characterization of HIV-1 vectors with gammaretrovirus envelope glycoproteins produced from stable packaging cells.

Authors:  B L Strang; Y Ikeda; F-L Cosset; M K L Collins; Y Takeuchi
Journal:  Gene Ther       Date:  2004-04       Impact factor: 5.250

3.  Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy.

Authors:  Ming-Jie Li; James Kim; Shirley Li; John Zaia; Jiing-Kuan Yee; Joseph Anderson; Ramesh Akkina; John J Rossi
Journal:  Mol Ther       Date:  2005-08-22       Impact factor: 11.454

4.  Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery.

Authors:  N D Mazarakis; M Azzouz; J B Rohll; F M Ellard; F J Wilkes; A L Olsen; E E Carter; R D Barber; D F Baban; S M Kingsman; A J Kingsman; K O'Malley; K A Mitrophanous
Journal:  Hum Mol Genet       Date:  2001-09-15       Impact factor: 6.150

Review 5.  Lentiviral vectors: a versatile tool to fight cancer.

Authors:  P U Emeagi; C Goyvaerts; S Maenhout; J Pen; K Thielemans; K Breckpot
Journal:  Curr Mol Med       Date:  2013-05       Impact factor: 2.222

Review 6.  Gene therapy for cancer: what have we done and where are we going?

Authors:  J A Roth; R J Cristiano
Journal:  J Natl Cancer Inst       Date:  1997-01-01       Impact factor: 13.506

7.  Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates.

Authors:  Virginie Sandrin; Bertrand Boson; Patrick Salmon; Wilfried Gay; Didier Nègre; Roger Le Grand; Didier Trono; François-Loïc Cosset
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

8.  Membrane fusion activity of vesicular stomatitis virus glycoprotein G is induced by low pH but not by heat or denaturant.

Authors:  Yi Yao; Kakoli Ghosh; Raquel F Epand; Richard M Epand; Hara P Ghosh
Journal:  Virology       Date:  2003-06-05       Impact factor: 3.616

9.  Exclusive Transduction of Human CD4+ T Cells upon Systemic Delivery of CD4-Targeted Lentiviral Vectors.

Authors:  Qi Zhou; Katharina M Uhlig; Anke Muth; Janine Kimpel; Camille Lévy; Robert C Münch; Janna Seifried; Anett Pfeiffer; Alexandra Trkola; Cheick Coulibaly; Dorothee von Laer; Winfried S Wels; Udo F Hartwig; Els Verhoeyen; Christian J Buchholz
Journal:  J Immunol       Date:  2015-07-31       Impact factor: 5.422

10.  CD19 and CD20 targeted vectors induce minimal activation of resting B lymphocytes.

Authors:  Sabrina Kneissl; Qi Zhou; Michael Schwenkert; François-Loic Cosset; Els Verhoeyen; Christian J Buchholz
Journal:  PLoS One       Date:  2013-11-11       Impact factor: 3.240

View more
  6 in total

1.  A humanized mouse-based HIV-1 viral outgrowth assay with higher sensitivity than in vitro qVOA in detecting latently infected cells from individuals on ART with undetectable viral loads.

Authors:  Paige Charlins; Kimberly Schmitt; Leila Remling-Mulder; Louise E Hogan; Emily Hanhauser; Kristen S Hobbs; Frederick Hecht; Steven G Deeks; Timothy J Henrich; Ramesh Akkina
Journal:  Virology       Date:  2017-04-19       Impact factor: 3.616

2.  Characterization of Antibody Interactions with the G Protein of Vesicular Stomatitis Virus Indiana Strain and Other Vesiculovirus G Proteins.

Authors:  Altar M Munis; Maha Tijani; Mark Hassall; Giada Mattiuzzo; Mary K Collins; Yasuhiro Takeuchi
Journal:  J Virol       Date:  2018-11-12       Impact factor: 5.103

Review 3.  Lentiviral Vector Bioprocessing.

Authors:  Christopher Perry; Andrea C M E Rayat
Journal:  Viruses       Date:  2021-02-09       Impact factor: 5.048

Review 4.  The Evolution of Gene Therapy in the Treatment of Metabolic Liver Diseases.

Authors:  Carlos G Moscoso; Clifford J Steer
Journal:  Genes (Basel)       Date:  2020-08-10       Impact factor: 4.096

5.  Lentivector Producer Cell Lines with Stably Expressed Vesiculovirus Envelopes.

Authors:  Maha Tijani; Altar M Munis; Christopher Perry; Khaled Sanber; Marta Ferraresso; Tarit Mukhopadhyay; Michael Themis; Ilaria Nisoli; Giada Mattiuzzo; Mary K Collins; Yasuhiro Takeuchi
Journal:  Mol Ther Methods Clin Dev       Date:  2018-08-07       Impact factor: 6.698

6.  CD46 Null Packaging Cell Line Improves Measles Lentiviral Vector Production and Gene Delivery to Hematopoietic Stem and Progenitor Cells.

Authors:  Stosh Ozog; Craig X Chen; Elizabeth Simpson; Olivia Garijo; Nina D Timberlake; Petra Minder; Els Verhoeyen; Bruce E Torbett
Journal:  Mol Ther Methods Clin Dev       Date:  2018-11-24       Impact factor: 6.698

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.